History of DM Capital
  • 2001
  • Founding

    DM Research and Consulting (Hong Kong) Ltd. (DMR) was established in 2001, specialized in company and sector research. DMR sold investment reports on public and private companies to many global funds and investors supported with in-depth due diligence operations in China

  • 2004
  • Hong Kong Stock Investments

    DM Capital started managing discretionary accounts by investing in public companies listed in Hong Kong. We developed a style of Constructive Activism after a dozen or so successful stock investments. Case in point: Wego (01066.HK), in which we helped the Company to grow from HKD 500 million to 50 billion in Chinese medical devices market, where it became the dominant player. The portfolio returned more than 10 times over by 2007 after we liquidated all positions and DM started direct investment operations in 2008.

  • 2007
  • Private Equity Investments

    During the period of 2007-2009,through its wholly owned subsidiary, DM Healthcare Investment Ltd. (formerly named China Medical Device Group Limited), DM Capital was the controlling shareholder of Longlife Group Holdings Limited (08037.HK). The DM team directly lead the successful restructuring of the Company, which boasted a workforce of 11,000 employees. DM Healthcare also invested directly in several private companies in the Chinese healthcare industry including Angel Dental, which became the largest Chinese invisible alignment company.

  • 2010
  • Harmony Healthcare Fund

    DM Capital launched the Harmony Healthcare Fund (harmonyfund.com) on July 21, 2010. It is a Constructive Activist Fund investing into Chinese healthcare companies listed in the global markets. It has invested in emerging pharmaceutical leaders such as Grand Pharma (00512.HK), which grew from a ranking of 150 in 2010 to currently 38th position in Chinese pharmaceutical companies.

  • 2014
  • Essence DM Dental Fund

    DM Capital founded Essence DM Fund Management Company in Shenzhen to manage the Essence DM Dental Fund, a private equity fund focused on the Chinese dental sector. Limited partners include Straumann AG of Switzerland, Essence Capital, and the Foshan Municipal Government of Guangdong Province. This is one of the only two funds globally specializing in the dental industry. It laid the foundation for DM to practice its concentrated sector investment strategy and value creation programs along industry value chains.

  • 2017
  • DM Medical Angel Fund I - AI Medical Fund

    The Fund was established by DM Capital to identify leading artificial intelligence technology companies in the medical industry. The portfolio consists of Chinese leaders in diabetes detection, lung cancer detection, dental treatment design and planning.

  • 2018
  • Asia Regenerative Medicine Limited

    In 2018, Asia Regenerative Medicine, a cell and organ regeneration technology company focused on diabetes, kidney and liver diseases, was jointly founded by DM Partners and professors from Universities in Hong Kong, Shenzhen, and Guangzhou. Asia Regenerative Medicine aims to integrate industrial resources at home and abroad and to become the flagship in regenerative medicine industry in China.

  • Regenerative Medicine Fund

    In 2018, DM Capital began investing in cell therapy and organ regeneration technology companies. The DM Regenerative Medicine Fund is looking for both limited partners with capital and new projects for investments. The first two investments are Iviva Medical in Boston and Asia Regenerative Medicine in China.

  • 2020
  • Megawave Healthcare Fund

    Specialized funds that focus on high growth market segments in the healthcare industry.
  • 2021
  • DM Financial Advisory

    Based on DM Capital's experienced advisory capabilities, we provide financial advisory and strategic consulting services based on the demand of our peers and portfolio companies.

©2018 DM Capital Ltd. All rights reserved